Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717 · CYPRESS Phase 3Active, not recruiting
- Lead sponsor
- Theravance Biopharma (Industry)
- Enrollment
- 102 (estimated)
- Start date
- 27 Jun 2023
- Primary completion
- Jan 2026 (estimated)
- Study completion
- 1 Jan 2028
- Last update posted
- 5 Sep 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- Ampreloxetine Drug
- Placebo Drug
Conditions and primary outcome
- Symptomatic Neurogenic Orthostatic Hypotension
- MSA - Multiple System Atrophy
Primary outcome
Change in OHSA composite score at Week 8 during the double-blind RW period (8-week randomized withdrawal period (Week 12 to Week 20))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05696717.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05696717 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.